tbuckley/cabot-search huggingface dataset:
AB0903 Is There Any Relationship between the Children Health Assessment Questionnaire (CHAQ) and the European Quality of Life (EUROQOL) in Children Suffering from Chronic Haemophilic Arthropathy?: Table 1
Authors: L. Medrare, A. Ngeuleu, M. Rkain, I. Bouaddi, F. Znat, S. El Kabbaj, T. Lakhdar, I. Benslama, H. Rkain, F. Allali, M. Khattab, M. El Khorassani, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> We aimed to analyze in children suffering from chronic haemophilic arthropathy relation between there functional impact and there quality of life. <h3>Methods</h3> Twenty- three children (mean age of 10.9±3.5 years [4-18]) suffering from severe haemophilia (median disease duration of 12 months (6; 18),median diagnosis delay of 0 months (0, 7)) were included. Functional impairment and quality of life were respectively assessed by the Moroccan versions of Children Health Assessment Questionnaire (CHAQ) and the European Quality of Life (the EUROQOL). A statistical analysis was conducted to determine the correlation between these two parameters using the r of Spearman <h3>Results</h3> Chronic haemophilic arthropathy affected knee, elbow, ankle and wrist in respectively 50, 27.5, 20 and 2.5%. Median CHAQ was 0.37 (0, 1.25). EUROQOL domains were affected as following: Mobility (69.6%),usual activity (65.2%), self-care (65.2%), anxiety/depression (43.4%) and pain (34.7%) Table 1 summarize correlation between the CHAQ and the 5 domains of EUROQOL. <h3>Conclusions</h3> This study suggests that the functional impact of chronic haemophilic arthropathy in children affected by severe hemophilia seems mainly related to the domains of mobility, self-care and usual activity of the EUROQOL. Further studies are required to verify those results. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4867
Abstract 37: CCN6 downregulation in invasive breast carcinomas: In situ characterization of changes in EMT proteins and metastatic disease
Authors: Guadalupe Lorenzatti, María Elena Gonzalez, Kathy A. Toy, Ana M. Cabanillas, Celina G. Kleer
Journal: Cancer Research (2012)

Abstract Background: The recognized heterogeneity of invasive breast carcinomas is a result of intrinsic characteristics of the tumor cells and their interaction with the microenvironment. CCN6, an extracellular matricellular protein involved in cell communication and epithelial-stromal interactions has a tumor suppressor role in breast cancer. CCN6 downregulation in benign breast cells induces an epithelial to mesenchymal transition marked by downregulation of E-cadherin and increased levels of the transcriptional regulators ZEB1 and Snai1. However, the relevance of these studies to human breast cancer needs further investigation. We hypothesized that CCN6 mRNA and protein levels in samples of breast cancer patients may be associated with metastasis and features of EMT. Methods: Forty clinical samples of invasive carcinoma and surrounding normal breast, frozen at the time of operation were collected. We extracted mRNA and protein from each sample and performed real time RT-PCR and Western blots for CCN6, respectively. All frozen samples were immunostained with antibodies against E-cadherin (BD Biosciences, 1:4000), ZEB1 (Santa Cruz Biotechnology, 1:400) and Snai1(Cell Signaling, 1:800). E-cadherin was analyzed as aberrant or normal. ZEB1 and Snai1 proteins were scored as positive or negative, either in the cancer or stromal cells. Results: Of the 40 frozen samples of breast cancer, 23 had high quality RNA and protein for further study. CCN6 mRNA and protein were both decreased in 18/23 (78%). Five of 23 (22%) samples exhibited normal or high expression. Low CCN6 was associated with the presence of distant metastasis. Four of 18 (22%) invasive carcinomas with low CCN6 had distant metastasis compared to none of the normal CCN6 expressing tumors (p&amp;lt;0.05). Seventeen of 18 (94%) of invasive carcinomas with low CCN6 had aberrant E-cadherin protein expression. We noted that in the tumors with aberrant E-cadherin protein, the expression of ZEB1 or Snai1 was mutually exclusive in all cases (p&amp;lt;0.05). We noted that 80% of the tumors exhibited ZEB1protein in the stromal cells. Conclusions: Our results show a direct link between levels of CCN6 mRNA and protein in breast carcinoma patient samples. A decrease in CCN6 expression in the primary breast cancer is associated with distant metastasis and decreased E-cadherin. We uncover a novel inverse relationship between ZEB1 and Snai1 proteins in breast cancer, which is under further investigation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 37. doi:1538-7445.AM2012-37
Abstract 5351: Phosphorylation of EZH2 at Thr487 is a marker for good prognosis in pancreatic cancer patients.
Authors: Yongkun Wei, Shih-Shin Chang, Huamin Wang, Weiya Xia, Mien-Chie Hung
Journal: Cancer Research (2013)

Abstract EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27). EZH2 is overexpressed in multiple tumor types and correlates with poor prognosis. We have previous shown that phosphorylation of EZH2 at Thr 487 by CDK1 inhibits its methyltransferase activity. However, the status of phosphorylation of EZH2 at Thr 487 (P-EZH2-T487) and its clinical implication in cancer patients have not been reported. We thus examined P-EZH2-T487 by immunohistochemistry and its association with prognosis in pancreatic cancer patients. We found that P-EZH2-T487 can be seen in 61% (47/77) of pancreatic cancer. In univariate survival analysis, patients with high P-EZH2-T487 had significantly longer overall survival time when compared with those with low P-EZH2-T487 (P=0.032). In multivariate analysis, P-EZH2-T487 was an independent prognostic marker for overall survival in pancreatic cancer (HR=0.358, P=0.001). These results suggest that P-EZH2-T487 is a prognostic indicator for clinical outcome in pancreatic cancer patients. Citation Format: Yongkun Wei, Shih-Shin Chang, Huamin Wang, Weiya Xia, Mien-Chie Hung. Phosphorylation of EZH2 at Thr487 is a marker for good prognosis in pancreatic cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5351. doi:10.1158/1538-7445.AM2013-5351 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Abstract 1116: Neurotensin high affinity receptor 1 is a functional biomarker for lung and breast cancer progression
Authors: Van Kien Doan, Sadi Menad Ahmed Zaïd, Mohamad Younes, Sandra Dupouy, Najat Mourra, Olivier De Wever, Marco Alifano, Anne Gompel, Patricia Forgez
Journal: Cancer Research (2011)

Abstract Neurotensin (NTS) is a 13 amino acid peptide, exerting hormonal and neurocrine regulation within the gastrointestinal tract to globally facilitate nutriment digestion. NTS action is mainly mediated by the high affinity G protein coupled neurotensin receptor, NTSR1. Abnormal expression of NTSR1 occurs during the early stages of cell transformation in relation with the deregulation of the Wnt/beta catenin pathway. Consequently, the oncogenic effects previously described for NTS in different types of cancer cells could presumably contribute to tumor progression. In order to establish this concept, we observed that NTS and NTSR1 were concomitantly expressed in human breast ductal carcinomas and lung adenocarcinomas. NTSR1 was found to be an independent prognostic marker in lung and breast clinical studies. Cellular models were developed in which NTS or NTSR1 was either abolished by sh-RNA or over-expressed. In experimental tumors using both models, active NTS autocrine or paracrine regulation caused the enhancement of tumor size and metastasis emergence when compared to those having poor expression of NTS or NTSR1. In vitro studies, confirmed that NTS enhancement of cellular growth, adherence, motility and invasion occurred through the activation of PKC, ERK 1/2 pathways, and by interfering with the network of epidermal growth factor tyrosine receptors, as EGFR, HER2, and HER3 expression and activation were increased. The use of NTSR1 specific antagonist and neutralizing NTS antibody confirmed the contribution of NTS in cellular oncogenic effect implicated in each step of cancer progression. Additionally, the activation of metalloprotease induced by NTS contributed to the release to EGF-like ligand. Our results suggest that the activation of the NTSR1 pathway causes an acceleration of the oncogenesis process within preexisting tumors by the up regulation of the three majors epidermal growth factor tyrosine receptors and the formation of autocrine stimulation of the HERs system. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1116. doi:10.1158/1538-7445.AM2011-1116
Transdiaphragmatic Resection of the Vagus Nerves for Peptic Ulcer
Authors: Francis D. Moore, William P. Chapman, Milford D. Schulz, Chester M. Jones
Journal: New England Journal of Medicine (1946)

DURING the last fifty years, a variety of surgical maneuvers have been developed for the treatment of cases of peptic ulcer ∥ that may be broadly termed as intractable to therapy but are otherwise uncomplicated. According to Allen,1 approximately 20 of every 100 patients suffering from peptic ulcer who present themselves to a physician do poorly under ordinary nonoperative methods of treatment. A sizable fraction of this group develop hemorrhage, perforation or cicatricial obstruction, obviously requiring surgical intervention. The remainder — estimated by Allen and Welch2 as 10 per cent — stand as medical failures or as intermittently sick patients. . . .
O170 DYSREGULATED UNFOLDED PROTEIN RESPONSE CONTROL IN THE ABSENCE OF CANONICAL IKK/NF-κB SIGNALLING LEADS TO SEVERE LIVER DAMAGE AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
Authors: Y. Sunami, M. Ringelhan, M. Lu, N. Hüser, E. Kakai, F. Leithäuser, J. Kleeff, D. Hartmann, S. Gul, S. Wissel, C. Brunner, P. Riedl, R. Schirmbeck, P. Strnad, M. Heikenwälder, T. Wirth
Journal: Journal of Hepatology (2014)
Effect of Growth Hormone Treatment on Adult Height of Children with Idiopathic Short Stature
Authors: Raymond L. Hintz, Kenneth M. Attie, Joyce Baptista, Alex Roche
Journal: New England Journal of Medicine (1999)

Short-term administration of growth hormone to children with idiopathic short stature results in increases in growth rate and standard-deviation scores for height. However, the effect of long-term growth hormone therapy on adult height in these children is unknown.
Abstract 846: Targeted inhibition of c-Met receptor by a selective c-Met inhibitor, Tivantinib, and a specific shRNA reduces breast cancer-derived bone metastases
Authors: Sara Previdi, Giovanni Abbadessa, Francesca Dalò, Dennis S. France, Massimo Broggini
Journal: Cancer Research (2012)

Abstract Breast cancer exhibits a propensity to metastasize to bone, resulting in debilitating skeletal-related complications associated with significant morbidity and mortality. Because of the clinical significance of this process, many research efforts are aimed at uncovering the molecular events in bone metastases to identify novel targets and to improve clinical management of metastatic bone disease. The interactions between metastatic cells and bone are critical to the development and progression of bone metastases, and their unravelling could lead to novel preventive or therapeutic approaches. We previously demonstrated the critical role of HGF/c-Met/β-catenin/TCF system in tumor-bone interaction leading to skeletal metastases of human breast cancer cells, suggesting the potential inhibition of this pathway in vivo. In this study, we evaluated the potential therapeutic efficacy of targeting the c-Met receptor by using both an oral, selective, small-molecule c-Met inhibitor, tivantinib, and a specific shRNA against c-Met in an experimental bone metastatic model of human breast cancer. Tivantinib exhibited dose-dependent anti-metastatic activity in vivo, and the 120 mg/kg dose, while being ineffective in reducing subcutaneous tumor growth, induced significant inhibition of bone metastatic growth and a noteworthy reduction of tumor-induced osteolysis. shRNA-mediated c-Met silencing did not affect in vitro proliferation of bone metastatic cells, but strongly reduced their migration, and this effect was further enhanced by tivantinib. These data were confirmed in vivo. Indeed, dual c-Met inhibition with both tivantinib and RNA interference strategy induces pronounced tumor growth suppression with concomitant marked decreases of lytic lesions and an improvement in survival. Overall, our findings highlighted the efficacy of c-Met inhibition in delaying the onset and progression of bone metastases and strongly suggested that targeting the c-Met receptor may have promising therapeutic value in the prevention and treatment of bone metastases from breast cancer. Most importantly, the finding that tivantinib is active as an anti-metastatic agent at low, non-cytotoxic doses suggests that its efficacy may be potentiated by combining it with other therapies that target cancer cell-bone interactions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 846. doi:1538-7445.AM2012-846
SP0029 Phenotyping Neck Pain in Order to Personnalize the Treatment
Authors: M. Revel
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> The first step of the diagnosis is to eliminate a specific disease: Infections, neoplastic conditions (bone and spinal cord) rheumatoid arthritis, spondylarthropathy, polymyalgia rheumatica, crystal depositions, ... All these diseases eliminated, the patient is presenting a common or regional neck pain. Considering all the situations of regional neck pain as a single disease is confusing. It is not the best way to optimize the treatments, mainly the rehabilitation. Adopting a simple classification could be clinically relevant. 1) Presence of a minor traumatism at the outset of the pain history: – Provide we are in whiplash grades 1 and 2 of the Quebec Task Force classification, mobilisation and strengthening exercises should be initiated soon. 2) Aged patient with obvious osteoarthritic changes in the cervical spine. – Pain is only induced when moving the neck, mainly in rotation. Provide there are no signs of myelopathy or radiculopathy, rehabilitation based on gentle mobilization and axial tractions can be usefull. – Pain is permanent, even during night. A pseudo inflammatory flare can be demonstrated by MRI images of oedema on end plates, or facet joints. NSAIDs and even corticosteroids have their best indication here. No indication of exercises. – C1/C2 location is a very disabling condition leading in some cases to a surgical fusion with excellent results. 3) The patient is younger with no changes on X rays. – Slight limitation of passive motion is observed generally in rotation with pain in the last degrees. We are probably at the first stage of unco vertebral and facet joints degeneration. Some beneficial effect of analgesics and NSAIDs This is the only situation where manipulations can be allowed. Exercises are indicated. – Passive motions are normal and painless. Pain is perceived after long postures in flexed position along the trapezius muscles. The patient is often a woman with a slim long neck. Analgesics have a mall effect Strengthening of the dorsal neck muscles should be indicated – Similar conditions with various locations of pain including headache and trigger points close to those observed in fibromyalgia. Sleep disturbance is often recorded. Better effect of antidepressants than analgesics, NSAIDs and rehabilitation. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6314
OP0177 Efficacy and safety of high vs. low dose etanercept in children with JIA
Authors: N. Tzaribachev, R. Voellm, G. Horneff
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> The TNF Alpha (TNFA) antagonist etanercept (ETN) is approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA) in a dose of 0.8 mg/kg/week. The existing data for TNFA other than ETN suggest a higher efficacy if higher doses are applied. <h3>Objectives</h3> To evaluate the efficacy and safety of ETN in doses &gt;0.8 mg/kg/week in JIA patients. <h3>Methods</h3> Data from the German Etanercept BIKER Registry were evaluated. Patients were divided into three groups: high dose (HD) (&gt;0.8 mg/kg/week), low (standard) dose (LD) (≤0.8mg/kg/week) and mixed dose (MD) (switching between (&gt;0.8 and ≤0.8mg/kg/week). Efficacy was measured by the PedACR score 30, 50, 70 after 3, 6 and 12 months of treatment. Safety analysis was performed by counting the number of adverse events (AE) per group and per patient. Last observation carried forward (LOCF), intention to treat (ITT) and per protocol (PP) data processing was applied. Statistically Kruskal-Wallis and χ<sup>2</sup>-tests were used. <h3>Results</h3> 547 patients (358 females) with a median age at registry entry of 6.6 years were evaluated: 264 in HD, 109 in the LD and 174 in MD groups. <i>Efficacy:</i> Independently of the data processing method (LOCF, ITT, PP), efficacy was similar irrespective of the dose. Differences between HD, LD and MD groups could not reach statistical significance. Interestingly the number of patients reaching a higher PedACR score increased with the duration of ETN-treatment, e.g. in the ITT analysis 38.9% of patients reached a PedACR 70 at 3 months of treatment vs. 59.6% at 12 months. <i>Safety:</i> A total of 72 AE occurred. Divided by the three treatment groups these were: 40 (15.15%) in the HD, 13 (11.93%) in the LD and 19 (10.92%) in the MD groups. The difference could not reach statistical significance (p=0.40). <h3>Conclusions</h3> Higher doses of ETN in children with JIA do not seem to add additional benefit to the treatment result. No statistically significant differences could be found between the three treatment groups and therefore in contrast to other TNF Alpha antagonists higher doses shouldn't be recommended to improve outcome. The duration of treatment with ETN seems to have a positive effect on the response rate to the drug. <h3>Disclosure of Interest</h3> None Declared
ENERGY/UNIFORMITY PERFORMANCE OF A NEW DIGITAL GAMMA CAMERA
Authors: S. Bello, M. W. Groch, S. M. Leonard, P. E. Moesbach, S. M. Spies
Journal: Clinical Nuclear Medicine (1996)

Bello, S.; Groch, M. W.; Leonard, S. M.; Moesbach, P. E.; Spies, S. M. Author Information
DOPPLER FLOW PATTERNS IN THE NEO-AORTA AND RIGHT VENTRICLE-TO-PULMONARY ARTERY SHUNT IN INFANTS WITH SINGLE RIGHT VENTRICLE ANOMALIES: IMPACT ON OUTCOME AFTER INITIAL STAGED PALLIATIONS
Authors: Peter C. Frommelt, Eric Gerstenberger, Jeanne Baffa, William Border, Timothy Bradley, Steven Colan, Jessica Gorentz, Haleh Heydarian, J. Blaine John, Wyman Lai, Jami Levine, Jimmy Lu, Rachel McCandless, Stephen Miller, Arni Nutting, Richard Ohye, Gail Pearson, Pierre Wong
Journal: Journal of the American College of Cardiology (2013)
Case 25-2002
Authors: Katherine McGowan, Eugene J. Mark
Journal: New England Journal of Medicine (2002)

Presentation of CaseA 46-year-old woman was admitted to the hospital because of extensive pulmonary infiltrates.The patient had felt well until several weeks before admission, when she began to have abdominal swelling and increasingly severe jaundice. Twenty-six days before admission, she entered another hospital, where evidence of hepatic cirrhosis was detected, along with severe anemia and notable encephalopathy. Tests for occult blood in the stool were positive. The ammonia level was greater than 150 μmol per liter, the ceruloplasmin level was 19 mg per deciliter, and the urinary copper level was normal; serologic tests for hepatitis A, B, and . . .
Right-Sided Colonic Diverticula as a Cause of Acute Rectal Hemorrhage
Authors: William J. Casarella, Ira E. Kanter, William B. Seaman
Journal: New England Journal of Medicine (1972)

Of 27 patients with acute rectal hemorrhage studied by emergency selective arteriography, the bleeding point was demonstrated in 18. Fifteen of these were in the colon, and 13 were secondary to diverticulosis. Twelve of the offending diverticula were located to the right of the splenic flexure. Nine were in the ascending colon. Emergency arteriography was the only method that consistently demonstrated the bleeding point in these patients. The location of the majority of bleeding diverticula in the ascending colon weighs strongly against the use of emergency sigmoid colectomy in this group of patients.
PWE-177 An Audit to Evaluate the Safety and Efficacy of Percutaneous Endoscopic Gastrostomy (PEG) Placement in Patients with Learning Disabilities
Authors: C Black, I Shaw, L Ayres
Journal: Gut (2013)

<h3>Introduction</h3> Guidelines exist to aid clinicians in selecting patients likely to benefit from percutaneous endoscopic gastrostomy (PEG) placement. Patients with learning disabilities (LD) are distinct from those with dementia in whom PEG placement in not usually recommended<sup>1</sup>. We report our experiences of PEG placement in patients with learning disabilities and our use of a specially designed pathway which emphasises multi-disciplinary team (MDT) input. <h3>Methods</h3> To describe the efficacy and safety of PEG insertion in patients with LD, we retrospectively analysed a cohort of 42 patients with severe LD who required nutritional support. We reviewed their medical case notes and their dietetic notes. <h3>Results</h3> Forty two patients underwent 117 procedures: 38 index PEG insertions, 43 PEG replacements, 35 percutaneous endoscopic gastrojejunostomy (PEGJ) replacements and 1 PEG removal (6 procedures (5.1%) were unsuccessful). Best interest meeting or MDT assessment took place in all patients. General anaesthetic was required for 34 (29%) procedures. Mean weight pre-PEG was 39.8 Kg and mean weight after a median follow-up of 21.5 months was 46.1 Kg (mean overall weight gain = 2.3 kg). 30 day mortality was zero. Complications were common (74%) and included perforation n = 1, aspiration pneumonia n = 13, tube displacement n = 10, PEG site infection n = 4. In 2 cases of unsuccessful PEG insertion surgical feeding gastrostomy was required. On-going vomiting occurred in 6 patients (14.3%) prompting conversion to PEG-J in 5 cases. <h3>Conclusion</h3> We found that PEG placement in LD patients was a positive intervention for the majority. Although there were frequent late complications such as aspiration pneumonia and PEG displacement, these reflect the complex underlying medical and social needs of the patients concerned. Overall, PEG placement appears to be safe and results in a modest weight gain; PEG-J should be considered for those with on-going vomiting. The use of a pathway for PEG placement ensures MDT input, appropriate patient selection, better pre-procedure planning e.g. use of general anaesthesia, and appears to promote good patient outcomes. <h3>Disclosure of Interest</h3> None Declared. <h3>Reference</h3> Westaby, D.<i> et al.</i> The provision of a percutaneously placed enteral tube feeding service. Gut 2010; 59: 1592–1605.
LOW CARDIAC OUTPUT STIMULATES VASOPRESSIN RELEASE IN PATIENTS WITH STAGE D HEART FAILURE: ITS RELEVANCE TO POOR PROGNOSIS AND REVERSAL BY SURGICAL TREATMENT
Authors: Teruhiko Imamura, Koichiro Kinugawa, Masaru Hatano, Hironori Muraoka, Takeo Fujino, Toshiro Inaba, Hisataka Maki, Osamu Kinoshita, Kan Nawata, Shunei Kyo, Minoru Ono
Journal: Journal of the American College of Cardiology (2014)